MEDC awards Kettering University $1.6 million to support programs bolstering Michigan manufacturing
Kettering University in Flint has received more than million dollars in economic development funds aimed at supporting programs in semiconductor manufacturing, hydrogen fuels, software engineering and engagement with pre-K through grade 12 students, according to a Thursday announcement.
As part of the Michigan Economic Development Corporation's Higher Education Strategic Initiatives the university was granted $1.6 million in an effort to bolster the state's advanced manufacturing efforts. Kettering also received funding to provide $5,000 and scholarships to students completing Co-ops in Michigan with select employers, alongside $10,000 incentives for students who commit to a full-time position, staying in Michigan for at least one year after graduation.
'Kettering University's experiential educational model has always been focused on developing leaders that will shape the future,' said University President Robert K. McMahan. 'This funding accelerates our ability to prepare Michigan's workforce while enhancing our capacity to equip it with the critical skills and hands-on experiences necessary to thrive in industries that will define the economy of the state for decades.'
The $1.6 million will be divided among the following programs:
$320,882 for semiconductor curriculum development
$354,202 for hydrogen fuels curriculum focused on the future of hydrogen fuel technologies
$287,432 for software engineering curriculum to develop new classes and acquire specialized equipment to prepare students for careers in software engineering and advanced systems development
$53,324 for Pre-K through 12 engagement, with the university launching summer hackathon camps to provide students with hands-on learning experience in engineering and advanced manufacturing.
The grants to Kettering are part of the nearly $30 million the Michigan Economic Development Corporation has invested into higher education institutions that are working with employers to prepare students for in-demand, mobility-related careers.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
6 hours ago
- Bloomberg
Wall Street Banks Boost Turkey Bets as Court Delay Brings Relief
JPMorgan Chase & Co. and Morgan Stanley are advising clients to buy Turkish bonds and the lira, after the postponement of a court ruling on a key opposition figure offered a reprieve from political risks. Strategists at both banks expect investors to shift their focus to Turkey's slowing inflation and the prospect for interest-rate cuts, which should bolster markets in the coming months.
Yahoo
7 hours ago
- Yahoo
"We're not looking for an endorsement deal, we're looking for co-branding" - LaVar Ball explained why Nike, Adidas, and Under Armour did not want to sign Lonzo to a shoe deal
"We're not looking for an endorsement deal, we're looking for co-branding" - LaVar Ball explained why Nike, Adidas, and Under Armour did not want to sign Lonzo to a shoe deal originally appeared on Basketball Network. Two months before the 2017 NBA Draft, top shoe brands Nike, Adidas, and Under Armour informed LaVar Ball that they had no intention of signing his son Lonzo to a shoe deal. Advertisement The younger Ball was a projected high lottery pick in that Year's draft after earning All-American first-team honors in his lone season at UCLA. However, after LaVar declared that he wanted a package shoe deal for his three sons worth $1 billion-plus collaboration with his company, Big Baller Brand, every major shoe player on the market shied away from Lonzo. "We've said from the beginning, we aren't looking for an endorsement deal," LaVar explained why nobody wanted his son. "We're looking for co-branding, a true partner. But they're not ready for that because they're not used to that model. But hey, the taxi industry wasn't ready for Uber, either." "Just imagine how rich Tiger, Kobe, Serena, Jordan, and LeBron would have been if they dared to do their own thing," He explained. "No one owned their own brand before they turned pro. We do and I have three sons so it's that much more valuable." LaVar already had a prototype of Lonzo's shoe Aside from Lonzo, LaVar had two other sons playing basketball. His second son, LiAngelo, was scheduled to enroll at UCLA that Year, while his youngest boy, LaMelo, had just finished his sophomore season at Chino Hills High School. Although it was only Zo who was going pro that Year, LaVar fearlessly predicted that all of his sons would be drafted into the NBA when their turn came, so that's why he was demanding a 'package deal'. Advertisement As for Lonzo's shoe, the elder Ball also boasted that he already has the prototype for his son's signature sneaker and is merely waiting for the right partner to produce it. "We're not going to sign with a company and then wait around for five or six years for a shoe like Paul George had to wait for with Nike," Ball added. "I've been working on that shoe ever since my boys were born." Big Baller Brand ended up making Lonzo's shoe A month after the interview, Lonzo's first signature shoe, the ZO2 Prime, was launched on the Big Baller Brand website and available for pre-order for a hefty price of $495. One year later, BBB made a second shoe for Zo called ZO2.19, which cost less than $200. Not long after, he disassociated himself with his father's brand after its co-founder could not account for a large sum of money he put into the business. Advertisement Meanwhile, Gelo went undrafted in 2018 and played in the G-League in 2021 but never got his career going. He is now a successful rapper. On the other hand, LaMelo was drafted third overall by the Charlotte Hornets in 2020 and won Rookie of the Year honors. LaMelo ended up signing a shoe deal with Puma. Just this Year, Puma released the fourth installment of Melo's shoe called MB.04. It has not been reported that Lonzo has a shoe deal with any brand. But most of the time, he wears different silhouettes of Kobe Bryant's Nike signature sneakers. The Big Baller Brand continues to sell shoes aside from apparel on its website; however, there are no more basketball shoes in its catalogue. Related: Paul Pierce thinks the Ball family deserves a movie: "It's lit that they all found their lane" This story was originally reported by Basketball Network on Jun 22, 2025, where it first appeared.
Business Wire
7 hours ago
- Business Wire
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
